Author’s response to reviews

Title: Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

Authors:

Yukinori Ozaki (1755ozaki@gmail.com)
Junichi Shindoh (shindou-tky@umin.ac.jp)
Wataru Gono (watapi-tky@umin.net)
Yujiro Nishioka (yutan21woodstock@gmail.com)
Chihiro Kondoh (ckondoh@toranomon.gr.jp)
Yuko Tanabe (ytanabe@toranomon.gr.jp)
Shuichiro Matoba (s-matoba@ac.cyberhome.ne.jp)
Hiroya Kuroyanagi (kuroyanagi@toranomon.gr.jp)
Masaji Hashimoto (masaji.hashimoto@gmail.com)
Toshimi Takano (takano@toranomon.gr.jp)

Version: 1 Date: 05 Nov 2016

Author’s response to reviews:

Dear Catherine,

Thank you for your assistance.

I revised my manuscript as Editor's comments say.

Editor's comments:

1 - Please rewrite the first sentence in the second paragraph in the Background section.

→ I rewrote the sentence as below:

Although a size-based response evaluation according to the RECIST is the gold standard,[3] some reports suggested the morphologic change should be taken into account especially in patients treated with a regimen that includes bevacizumab.[4-10]
2 - Please indicate whether written informed consent was obtained from the human subjects. If study approval or written human subject consent were not necessary, please state this in the manuscript and include a brief explanation.

→ I revised as below:

Ethics approval

We have obtained the approval of the ethics committee in Toranomon Hospital. It is difficult to obtain the written informed consent from the human subjects, and we provide the information on the website.

Consent for publication

We provide the information on the website because we could not obtain written informed consent from the human subjects.

Best regards,

Junichi Shindoh